Mr. Marc Edwards reports

KANE BIOTECH ANNOUNCES CANADIAN DISTRIBUTION AGREEMENT WITH BEST BUY MEDICAL FOR REVYVE™ ANTIMICROBIAL WOUND GEL

Kane Biotech Inc. has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve anti-microbial wound gel product line.

In November, 2024, Kane Biotech received Health Canada approval for its revyve anti-microbial wound gel, marking a significant milestone for the company in advancing wound care solutions. Since then, Kane has been actively working to promote the product and integrate it into the Canadian health care system. Through strategic partnerships, educational initiatives and engagement with health care professionals, the company has been focused on demonstrating revyve's effectiveness in infection management and wound healing. By increasing awareness and accessibility, Kane aims to establish revyve as a trusted solution in hospitals, clinics and long-term care facilities across Canada.

"This partnership with Best Buy Medical allows us to improve access to innovative wound care solutions for Canadians suffering from chronic, non-healing wounds," said Marc Edwards, president and chief executive officer of Kane Biotech. "By expanding our distribution network, we are not only helping patients and health care providers access effective infection management and wound healing solutions, but we are also tapping into a significant financial opportunity in the Canadian wound care market."

"We are excited to partner with Kane Biotech to bring the revyve anti-microbial wound gel to the Canadian market," said Jamie Church, chief executive officer of Best Buy Medical. "This collaboration aligns with our mission to offer the highest-quality medical products that enhance patient care and outcomes. We believe that revyve will be a game-changer in wound care management."

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Kane has a portfolio of biotechnologies, intellectual property (65 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research expertise and acquired from leading research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm and revyve are trademarks of Kane Biotech. Kane is listed on the TSX Venture Exchange under the symbol KNE and on the OTCQB Venture Market under the symbol KNBIF.

We seek Safe Harbor.